Anirban Maitra, MD, FCAP, MBBS, discusses the functional role for KRAS mutations in pancreatic cancer. “These studies show that KRAS inhibition works, but monotherapy delivers only a transient response, especially when dealing with late-stage tumors,” Dr. Maitra said.
For the full article click here: Combining immunotherapy with KRAS inhibitor eliminates advanced KRAS-mutant pancreatic cancer in preclinical models